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Nanomedicine is the indispensable enabling technology 
for the medicine of the future, encompassing molecular 
precision diagnosis, in vivo molecular imaging and tar-
geted individualized therapies leading to personalized 
medicine.
Infectious diseases, including “old” diseases like 
tuberculosis, malaria as well as more recent, but equally 
widespread threats like HIV infection and the anticipated 
Zika virus epidemia belong to the major threats for health 
and human well being and are considerable burdens for 
individuals and healthcare systems.
Nanomedicine has delivered and will further con-
tribute new tools for preventing infections (e.g. through 
nano-structured surfaces inhibiting bacterial coloniza-
tion), for diagnosing infections early [e.g. through micro/
nano-based rapid testing, microfluidic-based miniaturized 
immunoassays and novel nucleic acid testing strategies 
(1–4)], for treating such infections in a targeted fashion, 
with the goals to cure (5) such diseases in the short term 
in an individual and in the long term, to eradicate (6) such 
diseases entirely.
As the progress in experimental nanomedicine in the 
new millennium has been breath-taking at the technical 
level, it is now the prime time for broad translation of such 
academic achievements towards clinical application. 
In view of this long-term goal of individual and societal 
benefit through industrial and clinical translation, it is of 
critical importance to identify translation roadblocks (7) 
and to find optimal matches between biomedical require-
ments, technical solutions, manufacturing issues (8), 
regulatory paths, and in particular, to choose the clinical 
trials strategies wisely, as this aspect will determine the 
acceptance of new solutions by the medical community.
A new breed of nano scientists and in particular nano-
medical scientists is arising from its roots that range from 
experimental physics to pharmaceutics, from chemistry 
to biology, thereby radically changing the composition of 
academic research groups towards broad interdisciplinarity. 
However, even more interdisciplinarity is needed: Important 
fields of science are not yet well represented in nanomedi-
cine, although it is felt that they might contribute significantly 
to this field. For example, theoretical physics, computational 
science (9) and physical chemistry might contribute sig-
nificant aspects to deeper fundamental understanding, e.g. 
about the relevance of quantum effects in nanomaterials 
which may be much more important than we realize now. In 
a very different manner, the science of economics is urgently 
needed to delineate paths towards individually and soci-
etally affordable strategies for putting personalized medi-
cine into practice. Philosophical, ethical fundaments and 
social factors that have a critical impact on translation and 
that will play a major role in the practice of medicine based 
on novel technologies will need thorough analysis.
Nanomedicine, which is probably already now “the 
most interdisciplinary of all sciences”, will further profit 
from such a very broad vision of science, technology, medi-
cine and society. This journal, and the related CLINAM con-
ferences, will therefore continue to challenge scientists, 
physicians, industrial specialists, ethicists, regulators and 
government players, investors and all other stakeholders to 
contribute to such a comprehensive approach to medicine.
Such concerted efforts are needed for tackling the 
major challenges ahead in medicine, and in particular 
to overcome specific infectious diseases. For delivering 
a benefit to individuals and to mankind in rich and poor 
countries alike, such efforts are needed, are challenging, 
and will be highly rewarding not only to individuals and 
the healthcare systems benefiting from it, but also for 
those involved in making the future a reality.
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